EA200300640A1 - Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью - Google Patents
Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностьюInfo
- Publication number
- EA200300640A1 EA200300640A1 EA200300640A EA200300640A EA200300640A1 EA 200300640 A1 EA200300640 A1 EA 200300640A1 EA 200300640 A EA200300640 A EA 200300640A EA 200300640 A EA200300640 A EA 200300640A EA 200300640 A1 EA200300640 A1 EA 200300640A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- immunogeness
- immunogenicity
- antigens
- strengthening
- weak
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 230000005847 immunogenicity Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108010030416 proteoliposomes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к иммунологии, точнее к иммуногенным композициям, содержащим пептиды, полипептиды, белки и последовательности соответствующих им ДНК, клетки или их лизаты и протеолипосомы очень малого размера (VSSP), последние образуются путем связывания белкового комплекса наружной мембраны (CPME) Neisseria meningitidis с ганглиозидами посредством гидрофобных связей. В частности, в изобретении демонстрируют, как получать указанные иммуностимулирующие композиции, которые способны генерировать антиген-специфические иммунные ответы даже у иммунологически скомпрометированных хозяев, таких как пациенты, страдающие раком или хроническими вирусными или бактериальными инфекциями. Введением разработанных в изобретении вакцинных композиций пациентам можно восстанавливать участки их иммунной системы. Разработанные в изобретении вакцинные композиции можно применять для предупреждения или лечения инфекционных, злокачественных или аутоиммунных заболеваний.Отчет о международном поиске был опубликован 2002.12.27.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20000285A CU23000A1 (es) | 2000-12-06 | 2000-12-06 | Composiciones vacunales para la inmunoterapia activa específica del cáncer |
CU20010167A CU23009A1 (es) | 2001-07-12 | 2001-07-12 | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos |
PCT/CU2001/000010 WO2002045746A2 (es) | 2000-12-06 | 2001-12-06 | Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300640A1 true EA200300640A1 (ru) | 2003-12-25 |
EA005138B1 EA005138B1 (ru) | 2004-12-30 |
Family
ID=38812545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300640A EA005138B1 (ru) | 2000-12-06 | 2001-12-06 | Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью |
Country Status (20)
Country | Link |
---|---|
US (1) | US7776342B2 (ru) |
EP (1) | EP1356822B1 (ru) |
JP (1) | JP4210519B2 (ru) |
KR (1) | KR100850473B1 (ru) |
CN (1) | CN1291755C (ru) |
AR (1) | AR031638A1 (ru) |
AT (1) | ATE485833T1 (ru) |
AU (2) | AU2002221519B2 (ru) |
BR (1) | BRPI0116013B8 (ru) |
CA (1) | CA2431188C (ru) |
DE (1) | DE60143363D1 (ru) |
DK (1) | DK1356822T3 (ru) |
EA (1) | EA005138B1 (ru) |
HK (1) | HK1063726A1 (ru) |
MX (1) | MXPA03005032A (ru) |
NZ (1) | NZ526282A (ru) |
PE (1) | PE20020572A1 (ru) |
UY (1) | UY27059A1 (ru) |
WO (1) | WO2002045746A2 (ru) |
ZA (1) | ZA200304411B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
EP1367395A1 (de) * | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
AR045815A1 (es) * | 2003-10-09 | 2005-11-16 | Ct Ingenieria Genetica Biotech | Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano |
WO2005111079A2 (en) * | 2004-05-14 | 2005-11-24 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41 |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
PT2654785T (pt) * | 2010-12-22 | 2019-06-25 | Bayer Ip Gmbh | Resposta imunitária melhorada em espécies bovinas |
KR101323845B1 (ko) * | 2011-01-21 | 2013-10-31 | 광주과학기술원 | 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물 |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
MX2015012461A (es) * | 2013-03-15 | 2016-08-08 | Bioven 3 Ltd | Proteinas sintéticas autoensamblables. |
CU24299B1 (es) * | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
US10105306B2 (en) * | 2013-09-17 | 2018-10-23 | Bestop Group Holdings Limited | Method of preparing a growth factor concentrate |
HK1194912A2 (en) * | 2013-09-17 | 2014-10-24 | Bestop Group Holdings Ltd | Growth factor concentrate and the use thereof |
CN106103467B (zh) * | 2014-03-11 | 2019-12-31 | 艾克斯-马赛大学 | 与细胞膜神经节苷脂相互作用的嵌合肽 |
EP3597214A1 (en) | 2017-03-15 | 2020-01-22 | Centro de Inmunologia Molecular | Method for the treatment of patients with carcinomas |
US12019073B2 (en) * | 2017-03-15 | 2024-06-25 | Centro De Inmunologia Molecular | Method for the treatment of patients with carcinomas |
AU2018341578B2 (en) * | 2017-09-27 | 2024-02-08 | L2 Diagnostics, Llc | ErbB peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer |
CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
CU20170173A7 (es) | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
CN109865137A (zh) * | 2019-01-23 | 2019-06-11 | 天德悦(北京)生物科技有限责任公司 | 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
IT1206250B (it) * | 1987-02-18 | 1989-04-14 | Ist Farmacoterapico It Spa | Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla- |
US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
EP0651656A1 (en) | 1992-07-08 | 1995-05-10 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
EP0657471B1 (en) * | 1993-12-09 | 2001-10-24 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6207170B1 (en) * | 1998-01-16 | 2001-03-27 | Biomira U.S.A., Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
-
2001
- 2001-11-29 PE PE2001001202A patent/PE20020572A1/es not_active Application Discontinuation
- 2001-12-05 AR ARP010105662A patent/AR031638A1/es not_active Application Discontinuation
- 2001-12-06 BR BRPI0116013-3 patent/BRPI0116013B8/pt not_active IP Right Cessation
- 2001-12-06 UY UY27059A patent/UY27059A1/es unknown
- 2001-12-06 DE DE60143363T patent/DE60143363D1/de not_active Expired - Lifetime
- 2001-12-06 CN CNB018215602A patent/CN1291755C/zh not_active Expired - Lifetime
- 2001-12-06 CA CA2431188A patent/CA2431188C/en not_active Expired - Lifetime
- 2001-12-06 EP EP01999387A patent/EP1356822B1/en not_active Expired - Lifetime
- 2001-12-06 JP JP2002547529A patent/JP4210519B2/ja not_active Expired - Lifetime
- 2001-12-06 AU AU2002221519A patent/AU2002221519B2/en not_active Expired
- 2001-12-06 DK DK01999387.2T patent/DK1356822T3/da active
- 2001-12-06 WO PCT/CU2001/000010 patent/WO2002045746A2/es active IP Right Grant
- 2001-12-06 AT AT01999387T patent/ATE485833T1/de active
- 2001-12-06 AU AU2151902A patent/AU2151902A/xx active Pending
- 2001-12-06 EA EA200300640A patent/EA005138B1/ru not_active IP Right Cessation
- 2001-12-06 MX MXPA03005032A patent/MXPA03005032A/es active IP Right Grant
- 2001-12-06 US US10/003,463 patent/US7776342B2/en active Active
- 2001-12-06 KR KR1020037007634A patent/KR100850473B1/ko active IP Right Grant
-
2003
- 2003-06-04 NZ NZ526282A patent/NZ526282A/en not_active IP Right Cessation
- 2003-06-05 ZA ZA200304411A patent/ZA200304411B/en unknown
-
2004
- 2004-08-30 HK HK04106497A patent/HK1063726A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR031638A1 (es) | 2003-09-24 |
CN1484532A (zh) | 2004-03-24 |
MXPA03005032A (es) | 2004-09-10 |
AU2151902A (en) | 2002-06-18 |
NZ526282A (en) | 2005-01-28 |
ZA200304411B (en) | 2004-07-29 |
ATE485833T1 (de) | 2010-11-15 |
BR0116013A (pt) | 2004-01-06 |
US20020136735A1 (en) | 2002-09-26 |
CA2431188A1 (en) | 2002-06-13 |
EP1356822B1 (en) | 2010-10-27 |
KR100850473B1 (ko) | 2008-08-07 |
WO2002045746A3 (es) | 2002-12-27 |
CN1291755C (zh) | 2006-12-27 |
AU2002221519B2 (en) | 2006-11-23 |
BRPI0116013B1 (pt) | 2018-07-24 |
EA005138B1 (ru) | 2004-12-30 |
UY27059A1 (es) | 2002-04-26 |
JP2004523494A (ja) | 2004-08-05 |
DK1356822T3 (da) | 2011-02-07 |
BRPI0116013B8 (pt) | 2021-05-25 |
PE20020572A1 (es) | 2002-07-31 |
JP4210519B2 (ja) | 2009-01-21 |
KR20030061838A (ko) | 2003-07-22 |
EP1356822A2 (en) | 2003-10-29 |
CA2431188C (en) | 2010-09-07 |
HK1063726A1 (en) | 2005-01-14 |
WO2002045746A2 (es) | 2002-06-13 |
DE60143363D1 (de) | 2010-12-09 |
US7776342B2 (en) | 2010-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300640A1 (ru) | Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью | |
DK1002110T3 (da) | Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner | |
ES2141750T5 (es) | Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno. | |
EP2275552A3 (en) | Neisserial antigenic peptides | |
GB2255093A (en) | Hiv-1 core protein fragments | |
DK1098910T3 (da) | Antigenkompleks indeholdende immunstimulerende peptid, CD4 og chemokinreceptordomæne til behandling af HIV og immunsygdomme | |
WO2007034489A3 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
ATE389397T1 (de) | Adjuvante zusammensetzungen | |
Gupta et al. | Vaccine adjuvants: the current necessity of life | |
AU2016201589B2 (en) | Peptide adjuvants | |
FR2636842B1 (fr) | Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion | |
ATE283065T1 (de) | Mehrzweckvakzine gegen umhüllte viren | |
ATE374244T1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
DK0952771T3 (da) | Hidtil ukendte saponinpræparater og anvendelser deraf | |
CN105031646A (zh) | 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物 | |
Messner et al. | Vaccine development based on S-layer technology | |
MY129626A (en) | Preparations that potentiate immunogenicity in low immunogenic antigens | |
CU23009A1 (es) | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos | |
ES2353857T3 (es) | Composiciones farmacéuticas que mejoran la inmunogenicidad de antígenos poco inmunogénicos. | |
AU2001281943A1 (en) | The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof | |
Pumpens et al. | Presentation of virus-neutralizing epitopes on the surface of chimeric viral capsids | |
Chengua et al. | Gene fusion of cholera toxin B subunit with HBV PreS epitope and overexpression in E. coli | |
Jenkins et al. | Enhanced delivery systems for enteric antigen uptake in teleosts | |
Smith et al. | Potential for GTF-based synthetic peptides in a dental caries vaccine | |
CN104744594A (zh) | 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY |
|
MK4A | Patent expired |
Designated state(s): RU |